{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:01:18Z","timestamp":1788566478565,"version":"build-2803163510"},"reference-count":162,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2024,10,2]]},"DOI":"10.1080\/13543776.2024.2403634","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T05:06:18Z","timestamp":1726290378000},"page":"963-1007","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["MEK inhibitors in oncology: a patent review and update (2016 \u2013 present)"],"prefix":"10.1080","volume":"34","author":[{"given":"Anjali","family":"Suryavanshi","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Vandana","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugal Kishor","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and Research University, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragya","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Asati","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debarshi Kar","family":"Mahapatra","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj K.","family":"Keservani","sequence":"additional","affiliation":[{"name":"Faculty of B. Pharmacy, CSM Group of Institutions, Prayagraj, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanmati Kumar","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay Kumar","family":"Bharti","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20050908"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.00031-10"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202000646"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204083"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1039\/D2RA05751D"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc4000"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1039\/D3MD00145H"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101618"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2006.10.001"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2007.01.012"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3563"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2007.05.001"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2006.11.006"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.2174\/157436209788167466"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2438"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2017.1339688"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/02699050500284218"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1994"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2008.148"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/bfgp\/els022"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4281"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2009.01.022"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1503"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.17.7686"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/10533"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-3-8"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3760"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.8691"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3847"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09454"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature00766"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2200"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.246"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.207"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.8.12.8606"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.7.21.6919"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.8.12.8810"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.8.12.8809"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.21602"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.6.11.5167"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1089\/rej.2008.0722"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2007.01.004"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.7.17.6626"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.7.21.6965"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.8.12.8815"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2011-1304"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1150"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040829"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408868"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834014566428"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22101551"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.770475"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-013-0336-2"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0445"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-016-0374-3"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.83"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03443-6"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-020-00399-y"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.2147\/AHMT.S303456"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2483"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.10.008"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1311"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2013.11.013"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27790"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30180-8"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0963-x"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2020.1746265"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2015.09.023"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.10.054"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.04.008"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM10-2516"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2011.01.071"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-13-B75"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00714-0"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28236"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2011.01.062"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2016.1139231"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2017.12.019"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113386"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0066"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0832"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2019.04.009"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-27"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2015.10.001"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.08.026"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.1090"},{"key":"e_1_3_5_89_1","unstructured":"Decorte BL Doodeman R Henk R et al. Inventor; immuneering corporation. assignee. MEK inhibitors and therapeutic uses thereof. AU-2021206684-B2. 2024."},{"key":"e_1_3_5_90_1","unstructured":"Patterson K Liu J Couch RW et al. Inventor; springworks therapeutics inc. assignee. Crystalline solids of MEK inhibitor n-((r)-2 3-dihydroxypropoxy)-3 4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof. US-11884610-B2. 2024."},{"key":"e_1_3_5_91_1","unstructured":"Aay N Anand NK Blazey CM et al. Inventor; exelixis inc. assignee. MEK inhibitors and methods of their use. US-11597699-B2. 2023."},{"key":"e_1_3_5_92_1","unstructured":"Allen S Blake J Blackmark S et al. Inventor; pfizer inc. assignee. 3 4-dihydro-2 7-naphthyridine-1 6(2h 7h)-diones as MEK inhibitors. TW-I825637-B. 2023."},{"key":"e_1_3_5_93_1","unstructured":"Chakrabarty S Monlish D Flaherty P et al. Inventor; Duquesne University of the holy ghost. assignee. Carboxylic acid ester prodrug inhibitors of MEK. CA-2889381-C. 2023."},{"key":"e_1_3_5_94_1","unstructured":"Ross BD Dort MV. Inventor; the regents of the university of Michigan. assignee. Multifunctional inhibitors of MEK\/PI3K and mTOR\/MEK\/PI3K biological pathways and therapeutic methods using the same. AU-2021202619-B2. 2022."},{"key":"e_1_3_5_95_1","unstructured":"Ai N Anand NK Bowers OJ et al. Inventor; excellis inc. assignee. Azetidines as MEK inhibitors for the treatment of proliferative diseases. CN-109053523-B. 2022."},{"key":"e_1_3_5_96_1","unstructured":"Ross BD Dort MV. Inventor; the regents of the university of Michigan. assignee. Inhibitors of MEK\/PI3K JAK\/MEK JAK\/PI3K\/mTOR and MEK\/PI3K\/mTOR biological pathways and methods for improving lymphatic uptake bioavailability and solubility of therapeutic compounds. US-11311624-B2. 2022."},{"key":"e_1_3_5_97_1","unstructured":"Scheidt KA Schiltz GE Clutter MR et al. Inventor; Northwestern University. assignee. 3-arylindazoles as selective MEK4 inhibitors. US-11370770-B2. 2022."},{"key":"e_1_3_5_98_1","unstructured":"Bock MG Joshi AA Kennedy AR et al. Inventor; novartis AG. assignee. Compounds and compositions as inhibitors of MEK. KR-102354208-B1. 2022."},{"key":"e_1_3_5_99_1","unstructured":"Chen S Gong Z Huang Y et al. Inventor; cstone pharmaceuticals cstone pharmaceuticals (Shanghai) Co. Ltd. cstone pharmaceuticals (Suzhou) Co. Ltd. assignee. Coumarin-like cyclic compound as MEK inhibitor and use thereof. AU-2018289864-B2. 2022."},{"key":"e_1_3_5_100_1","unstructured":"Garraway LA Emery C Wagle N. Inventor; dana-farber cancer institute inc. assignee. MEK1 mutation conferring resistance to RAF and MEK inhibitors. US-10788496-B2. 2020."},{"key":"e_1_3_5_101_1","unstructured":"Krell CM Misun M Niederer DA et al. Inventor; novartis pharma AG array biopharma inc assignee. Preparation of and formulation comprising a MEK inhibitor. US10729678B2. 2020."},{"key":"e_1_3_5_102_1","unstructured":"John TM Nadipalli PR Nyavanandi VK et al. Inventor; asana biosciences LLC. assignee. Quinazolines and azaquinazolines as dual inhibitors of RAS\/RAF\/MEK\/ERK and PI3K\/AKT\/PTEN\/mTOR pathways. AU-2014250836-B2. 2018."},{"key":"e_1_3_5_103_1","unstructured":"Ross B Dee D Dolt D et al. Inventor; the regents of the University of Michigan. assignee. MEK\/PI3K dual inhibitor and therapeutic method using the inhibitor. JP-6315848-B2. 2018."},{"key":"e_1_3_5_104_1","unstructured":"Lamb P. Inventor; exelixis inc. assignee. Methods of using MEK inhibitors. EP-2101759-B1. 2018."},{"key":"e_1_3_5_105_1","unstructured":"Dave BB Banerjee B Pukan RK et al. Inventor; lupin ltd. assignee. Heterocyclyl compounds as MEK inhibitors. JP-6431770-B2. 2018."},{"key":"e_1_3_5_106_1","unstructured":"Lulu W Fei L Yizhong Z et al. Inventor; capital pharmaceutical holdings (Beijing) Co ltd. assignee. A kind of preparation method of the intermediate of 6 arylamino pyridine ketone formamide MEK inhibitor compound. CN-107721894-A. 2018."},{"key":"e_1_3_5_107_1","unstructured":"Aay N Anand NK Blazey CM et al. Inventor; exelixis inc. assignee. Azetidines as MEK inhibitors for the treatment of proliferative diseases. AU-2017203996-A1. 2017."},{"key":"e_1_3_5_108_1","unstructured":"Chakrabarty S Monlish D Flaherty P et al. Inventor; duquesne univ of holy spirit. assignee. Carboxylic acid ester prodrug inhibitors of MEK. US 2017\/0096388 A1. 2017."},{"key":"e_1_3_5_109_1","unstructured":"Junttila M. Inventor; genentech inc. assignee. Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors. US 2017\/0112925 A1. 2017."},{"key":"e_1_3_5_110_1","unstructured":"Maderna A Vernier JM Barawkar D et al. Inventor; ardea biociences inc. assignee. Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK. US 2017\/0183333 A1. 2017."},{"issue":"629","key":"e_1_3_5_111_1","first-page":"836 B2","article-title":"Inventor; novartis AG. assignee. Compounds and compositions as inhibitors of MEK","volume":"9","author":"Bock MG","year":"2017","unstructured":"Bock MG, Moebitz H, Panigrahi SK, et al., Inventor; novartis AG. assignee. Compounds and compositions as inhibitors of MEK. US. 2017;9(629):836 B2.","journal-title":"US"},{"key":"e_1_3_5_112_1","unstructured":"Lamb P. Inventor; exelixis inc. assignee. Methods of using MEK inhibitors. CA-2671982-C. 2016."},{"key":"e_1_3_5_113_1","unstructured":"Banerjee RK Dave B Hangarge R et al. Inventor; lupin ltd. assignee. Heterocyclyl compounds as MEK inhibitors. AU-2013234009-B2. 2016."},{"key":"e_1_3_5_114_1","unstructured":"Xiao D Zhu L Hu Y et al. Inventor; centaurus biopharma Co ltd chia tai tianqing pharmaceutical group Co ltd. assignee. Novel 6-arylamino pyridone carboxamide as MEK inhibitors. CA-2829117-C. 2016."},{"key":"e_1_3_5_115_1","unstructured":"Bock MG Moebitz H Panigrahi SK et al. Inventor; novartis AG. assignee. Compounds and compositions as inhibitors of MEK. AU2014307593C1. 2016."},{"key":"e_1_3_5_116_1","unstructured":"Lee G Jeon HS Jeon KJ et al. Inventor; asan foundation CMG pharmaceutical Co ltd. assignee. Substituted pyridinone compounds as MEK inhibitors. US-2016108041-A1. 2017."},{"key":"e_1_3_5_117_1","unstructured":"Dave B Banerjee RK Phukan S et al. Inventor; lupin ltd. assignee. Heterocyclyl compounds as MEK inhibitors. US 2016\/0331753 A1. 2017."},{"key":"e_1_3_5_118_1","unstructured":"Ooshio T Sonoshita M Ichikawa S et al. Inventor; tsuzuki educational institute hokkaido university NUC. assignee. Agent for treating or preventing cancer and combination of RF pathway inhibitor and MEK inhibitor for treating or preventing cancer. US11925646B2. 2024."},{"key":"e_1_3_5_119_1","unstructured":"Ebbing B Meyer H. Inventor; american genentech inc. assignee. Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors. TWI835048B. 2024."},{"key":"e_1_3_5_120_1","unstructured":"Maurer MA O\u2019quigley MG Holland J et al. Inventor; pfizer inc ideaya biosciences inc. assignee. Combination therapy comprising a pkc inhibitor and a MEK inhibitor. EP4322953A1. 2024."},{"key":"e_1_3_5_121_1","unstructured":"Castro AC Burke M Amidon B et al. Inventor; Ikena Oncology. assignee. Incorporated. Combination of the TEAD inhibitor 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide with an EGFR inhibitor and\/or a MEK inhibitor for use in the treatment of lung cancer. JP2024505196A. 2024."},{"key":"e_1_3_5_122_1","unstructured":"Audoly L Paudel BB Quaranta V. Inventor; duet biosystems inc. Vanderbilt university. assignee. Therapeutic methods and compositions for treating cancer using braf and\/or MEK inhibitor combination therapy. US20230084515A1."},{"key":"e_1_3_5_123_1","unstructured":"Blackman SC Venetsanakos E. Inventor; day one biopharmaceuticals inc. assignee. Combination of raf inhibitor and MEK inhibitor. US20240058338A1. 2024."},{"key":"e_1_3_5_124_1","unstructured":"Amidon B Burke M Castro AC et al. Inventor; ikena oncology inc. assignee. Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide TEAD inhibitor with an EGFR inhibitor and\/or MEK inhibitor for use in the treatment of lung cancer. AU2022210800A1. 2023."},{"key":"e_1_3_5_125_1","unstructured":"Zhai Y Yang D Fang DD et al. Inventor; ascentage pharma suzhou Co ltd ascentage pharma group Co ltd. assignee. Combination of IAP inhibitors and PARP or MEK inhibitors or other chemotherapeutic agents. US20230029259A1. 2023."},{"key":"e_1_3_5_126_1","unstructured":"Vilenchik M Frid M Kuznetsova A et al. Inventor; felicitex therapeutics inc. assignee. Combination cancer therapy with DYRK1 inhibitors and inhibitors of the Ras-Raf-MEK-ERK (MAPK) pathway. WO2023140846A1. 2023."},{"key":"e_1_3_5_127_1","unstructured":"Vilenchik M Frid M Kuznetsova A et al. Inventor; felicitex therapuetics inc. assignee. Combination cancer therapy with dyrk1 inhibitors and inhibitors of the Ras-Raf-MEK-ERK (MAPK) pathway. US20230226061A1. 2023."},{"key":"e_1_3_5_128_1","unstructured":"Merchant M Sampath D Konopleva MY et al. Inventor; genentech inc university of texas system. assignee. Combination of bcl-2 inhibitor and MEK inhibitor for the treatment of cancer. EP3370775B1. 2023."},{"key":"e_1_3_5_129_1","unstructured":"Ruscetti M Morris JP Lowe S. Inventor; memorial sloan kettering cancer center. assignee. Combination therapy with MEK inhibitor and CDK4\/6 inhibitor to treat pancreatic cancer. US11633401B2. 2023."},{"key":"e_1_3_5_130_1","unstructured":"Straussman R Gavert N Zwang Y. Inventor; yeda research and development Co. Ltd. the medical research infrastructure and health services fund of the Tel Aviv medical Center. assignee. Combination therapy with a MEK inhibitor and a s inhibitor for the treatment of colorectal cancer. WO2023031925A1. 2023."},{"key":"e_1_3_5_131_1","unstructured":"Hirai H Matsuoka K Miura A. Inventor; taiho pharmaceutical Co ltd. assignee. Cancer therapy using 3 5-disubstituted benzene alkynyl compound and MEK inhibitor. US20230165862A1. 2023."},{"key":"e_1_3_5_132_1","unstructured":"Fardis M. Inventor; iovance biotherapeutics inc. assignee. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with BRaf inhibitors and\/or MEK inhibitors. EP4259164A1. 2023."},{"key":"e_1_3_5_133_1","unstructured":"Maecker H Inventor IB Genentech. Inc. assignee. Pharmaceutical composition comprising a PD-1 axis binding antagonist and a MEK inhibitor. BR122022000334B1. 2023."},{"key":"e_1_3_5_134_1","unstructured":"Maecker H Irving B. Inventor; genentech inc. assignee. Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors. CA2843595C. 2022."},{"key":"e_1_3_5_135_1","unstructured":"Cross DAE Eberlein CA. Inventor; AstraZeneca AB. assignee. Combination of EGFR inhibitor and MEK inhibitor for use in the treatment of nras-mutated cancer. ES2890556T3. 2022."},{"key":"e_1_3_5_136_1","unstructured":"Wang J Chen J Miller DD et al. Inventor; university of tennessee research. assignee. Use of imidazole derivatives in combination with a Braf inhibitor or MEK inhibitor in the treatment of cancer. CA2904338C. 2022 Jul 5."},{"key":"e_1_3_5_137_1","unstructured":"Choong N. Inventor; genentech inc. assignee. Combination therapy with a mek inhibitor a PD-1 axis inhibitor and a VEGF inhibitor. EP3496752B1. 2022."},{"key":"e_1_3_5_138_1","unstructured":"Dumble M Kumar R Laquerre S et al. Inventor; novartis AG. assignee. Combination comprising an MEK inhibitor and a BRAF inhibitor. EP3560498B1. 2022."},{"key":"e_1_3_5_139_1","unstructured":"Rothbaum W Lannutti B Kaptein L. Inventor; acera pharma BV. assignee. Therapeutic combinations of a MEK inhibitor and a BTK inhibitor. US11154554B2. 2021."},{"key":"e_1_3_5_140_1","unstructured":"Cross DAE Eberlein CA. Inventor; AstraZeneca AB. assignee. Combination of EGFR inhibitor and MEK inhibitor for use in the treatment of NRAS mutated cancer. EP3125885B1. 2021."},{"key":"e_1_3_5_141_1","unstructured":"Merchant M Sampath D Konopleva MY et al. Inventor; genentech inc. assignee. University of texas system. Combination of bcl-2 inhibitor and MEK inhibitor for the treatment of cancer. CA3001880C. 2021."},{"key":"e_1_3_5_142_1","unstructured":"Jianjun Z Ruihua X Yi L. Inventor; medicine Co ltd. assignee. Use of a combination of a PD-1 antibody and a MEK inhibitor for the preparation of a medicament for the treatment of tumors. CN109663130B. 2021."},{"key":"e_1_3_5_143_1","unstructured":"Saha S Welsch D DeCrescenzo G et al. Inventor; biomed valley discoveries inc. assignee. Cancer treatments using combinations of type 2 MEK and ERK inhibitors. US11007184B2. 2021."},{"key":"e_1_3_5_144_1","unstructured":"Chakravarty A Vincent P. Inventor; takeda pharmaceutical Co ltd millennium pharmaceuticals inc. assignee. Combination of MEK inhibitors and selective inhibitors of aurora a kinase. EP2713727B1. 2021."},{"key":"e_1_3_5_145_1","unstructured":"Jian Y Man Z Cheng L. Inventor; jiangsu hengrui medicine Co ltd. assignee. Application of MEK inhibitor and androgen receptor antagonist in preparation of tumor treatment drug. CN111514140B. 2021."},{"key":"e_1_3_5_146_1","unstructured":"Porter D Emery C L TAN et al. Inventor; novartis AG. assignee. Pharmaceutical combinations of a PCK inhibitor and a MEK inhibitor for use in treatment of cancer. CA2892578C. 2021."},{"key":"e_1_3_5_147_1","unstructured":"Belvin M Moffat J Merchant M. Inventor; F hoffmann La roche AG. assignee. Combination of MEK inhibitors and ERK inhibitors for the treatment of hyperproliferative disorders. CN105517548B. 2020."},{"key":"e_1_3_5_148_1","unstructured":"Dumble M Kumar R Laquerre S et al. Inventor; novartis AG. assignee. Combination comprising an MEK inhibitor and a BRAF inhibitor. EP2488033B1. 2019."},{"key":"e_1_3_5_149_1","unstructured":"Dumble M Gilmer T Kumar R et al. Inventor; novartis AG. assignee. Combination of a MEK inhibitor and an AKT inhibitor to treat cancer. CA2775125C. 2019."},{"key":"e_1_3_5_150_1","unstructured":"Rothbaum W Lannutti B Kaptein A. Inventor; acerta pharma BV. assignee. Therapeutic combinations of a MEK inhibitor and a BTK inhibitor. US20190374539A1. 2019."},{"key":"e_1_3_5_151_1","unstructured":"Chen M Zhang Y Liu Q et al. Inventor; crystal pharmatech Co ltd. assignee. CDK inhibitor eutectic crystal of MEK inhibitor and preparation method therefor. EP3279201A1. 2019."},{"key":"e_1_3_5_152_1","unstructured":"Choong N. Inventor; genentech inc. (US). assignee. Combination therapy with a MEK inhibitor a PD-1 axis inhibitor and a VEGF inhibitor. WO2018031865A1. 2018."},{"key":"e_1_3_5_153_1","unstructured":"Garraway LA Emery C Wagle N. Inventor; dana farber cancer institute inc. assignee. A MEK1 mutation conferring resistance to RAF and MEK inhibitors. US20180217147A1. 2018."},{"key":"e_1_3_5_154_1","unstructured":"Ross BD Dort MV. Inventor; the regents of the university of michigan (us). assignee. Multifunctional inhibitors of MEK\/PI3K and mTOR\/MEK\/PI3K biological pathways and therapeutic methods using the same. WO2018009638A1. 2018 Jan 11."},{"key":"e_1_3_5_155_1","unstructured":"Srivastava SK Fofaria NM. Inventor; texas tech university system. assignee. Inhibitors of mcl-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors. US20180161313A1. 2018."},{"key":"e_1_3_5_156_1","unstructured":"Caponigro G Spirohn TH Lehar J. Inventor; novartis AG. assignee. Combinations of the CDK4\/6 inhibitor lee011 and the MEK 1\/2 inhibitor trametinib optionally further comprising the PI3K inhibitor byl719 to treat cancer. WO2017037574A1. 2017."},{"key":"e_1_3_5_157_1","unstructured":"Merchant M Sampath D Konopleva MY et al. Inventor; GENENTECH INC. assignee. Combination of bcl-2 inhibitor and MEK inhibitor for the treatment of cancer. WO2017079399A1. 2017."},{"key":"e_1_3_5_158_1","unstructured":"Rothbaum W Lannutti B Kaptein A. Inventor; acetra pharma B.V. assignee. Therapeutic combinations of a MEK inhibitor and a BTK inhibitor. WO2017033113A1. 2017."},{"key":"e_1_3_5_159_1","unstructured":"Belvin M Moffat J Merchant M. Inventor; genentech inc. assignee. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases. US9532987B2. 2017."},{"key":"e_1_3_5_160_1","unstructured":"Miner JN Chapman MS Quart B et al. Inventor; ardea biosciences inc. assignee. Combinations of MEK inhibitors and RAF kinase inhibitors and uses thereof. EP2175885B1. 2016."},{"key":"e_1_3_5_161_1","unstructured":"Garraway LA Emery C Wagle N. Inventor; dana farber cancer institute inc. assignee. MEK1 mutation conferring resistance to RAF and MEK inhibitors. US20160216266A1. 2016."},{"key":"e_1_3_5_162_1","unstructured":"Goodstal SA Elenbaas BA Ma J. Inventor; merck patent GMBH. assignee. Compositions and methods for MEK inhibitor combination therapy in the treatment of cancer. WO2016014390A1. 2016."},{"key":"e_1_3_5_163_1","unstructured":"Hoos A. Inventor; novartis AG. assignee. Combinations of an anti-pd-l1 antibody and a MEK inhibitor and\/or a BRAF inhibitor. US20160089434A1. 2016."},{"key":"e_1_3_5_164_1","unstructured":"Audoly L Paudel BB Quaranta V. Inventor; duet biosystems inc vanderbilt university. assignee. Therapeutic methods and compositions for treating cancer using BRAF and\/or MEK inhibitor combination therapy. US-2023084515\u2013A. 2023."}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2024.2403634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T08:43:45Z","timestamp":1727340225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2024.2403634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":162,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,2]]}},"alternative-id":["10.1080\/13543776.2024.2403634"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2024.2403634","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-05-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}